5 Key Takeaways

• 1

  CAR T cell therapy has transformed treatment for blood cancers but faces significant challenges in solid tumors.

• 2

  Mass spectrometry and proteomics are crucial for understanding CAR T function and improving therapy design.

• 3

  Solid tumors present unique barriers, including immunosuppressive environments and lack of exclusive cancer targets.

• 4

  Advanced analytics can enhance CAR T development by identifying effective targets and optimizing CAR constructs.

• 5

  There is a need for improved software and workflows to analyze complex proteomics data for CAR T therapy quality control.